Musikintervention und transkranielle Elektrostimulation bei neurologischen Erkrankungen
Musikintervention und transkranielle Elektrostimulation zur Behandlung neurologischer Erkrankungen
The goal of this clinical trial is to evaluate the efficacy of a musical interventionand non-invasive brain stimulation in neurological patients. The main questions it aims to answer are:
- to evaluate the residual neuroplastic processes in DOC state related to music exposure
- to determine the putative modulation of the aforementioned processes and the clinical outcome of DOC patients by non-pharmacological strategies, i.e., electric (tDCS) and music stimulation
- to evaluate the impact of this intervention on caregiver's burden and psychological distress.
Participants will be randomly assigned to one of three different music-listening intervention groups. Primary outcomes will be clinical, that is based on the neurologist's observations of clinical improvement, and neurophysiological, collected pre-intervention, post-intervention and post-placebo.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Simona Spaccavento
- Telefonnummer: +393332783524
- E-Mail: simona.spaccavento@icsmaugeri.it
Studienorte
-
-
Ba
-
Bari, Ba, Italien, 70025
- Rekrutierung
- Istituti Clinici Scientifici Maugeri
-
Kontakt:
- Simona Spaccavento
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Age > 18 years
- Post-stroke aphasia
- Post-stroke neglect
- Patients with disorders of consciusness (DOC)
Exclusion Criteria:
- No auditory injury
- no hystory of neurological disease
- No hystory of psychiatric disease
- Previous stroke
- use of alcohol and drugs
- premorbid dementia
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Doppelt
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Group 1
Group 1 will receive tEs combined with music stimulation for 2 weeks, 1 week of wash out, then sham stimulation combined with noise (placebo) for other 2 weeks. |
music |
|
Experimental: Group 2
Group 2 will receive sham stimulation and noise (placebo) for the first 2 weeks, then 1 week wash out, and finally tEs and music stimulation for other 2 weeks. |
music |
|
Experimental: Group 3
Group 3 will receive only music stimulation and sham stimulation for 2 weeks, 1 week of wash out, then sham stimulation and noise (placebo) for another 2 weeks. |
music |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Neuropsychological outcomes
Zeitfenster: Change from baseline Coma Recovery Scale- Revised at 2 weeks and 4 weeks
|
-Coma Recovery Scale-Revised (CRS-R) - (0-23). High score means a better outcome. |
Change from baseline Coma Recovery Scale- Revised at 2 weeks and 4 weeks
|
|
Neuropsychological outcomes
Zeitfenster: Change from baseline Disability Rating Scale at 2 weeks and 4 weeks
|
Disability Rating Scale (DRS) - (0-29). High score means a worse outcome. |
Change from baseline Disability Rating Scale at 2 weeks and 4 weeks
|
|
Neuropsychological outcomes
Zeitfenster: Change from baseline Rancho Levels of Cognitive Functioning at 2 weeks and 4 weeks
|
Rancho Levels of Cognitive Functioning (LCF) - (1-8). High score means a better outcome. |
Change from baseline Rancho Levels of Cognitive Functioning at 2 weeks and 4 weeks
|
|
Neuropsychological outcomes
Zeitfenster: Change from baseline Glasgow Outcome Scale- Extended at 2 weeks and 4 weeks
|
Glasgow Outcome Scale- Extended (GOS-E) - (1-8). High score means a better outcome. |
Change from baseline Glasgow Outcome Scale- Extended at 2 weeks and 4 weeks
|
|
Neuropsychological outcomes
Zeitfenster: Change from baseline Aachener Aphasie Test at 2 weeks and 4 weeks
|
Aachener Aphasie Test (AAT). This test includes six subtests: spontaneous speech, token test, repetition, written language, naming, and comprehension. Spontaneous speech is structured in six parts (0-30). High score means a better performance; Token test is composed by 50 items; for the score the number of error id considered (0-50). Repetition sub test is composed by 50 items; for each item the score range from 0 to 3; high score means better outcome (0-150). Written language subtest is composed by 30 items; for each item the score range from 0 to 3; high score means better outcome (0-90). Naming subtest is composed by 40 items; for each item the score range from 0 to 3; high score means better outcome (0-120). Comprehension subtest is composed by 40 items; for each item the score range from 0 to 3; high score means better outcome (0-120). |
Change from baseline Aachener Aphasie Test at 2 weeks and 4 weeks
|
|
Neuropsychological outcomes
Zeitfenster: Change from baseline Italian version of Functional Outcome Questionnaire for Aphasie at 2 weeks and 4 weeks
|
Italian version of Functional Outcome Questionnaire for Aphasie (FOQ-A) - (32-160). High score means a better outcome. |
Change from baseline Italian version of Functional Outcome Questionnaire for Aphasie at 2 weeks and 4 weeks
|
|
Neuropsychological outcomes
Zeitfenster: Change from baseline Functional Assessment Measure - Cognitive subscale at 2 weeks and 4 weeks
|
Functional Assessment Measure - Cognitive subscale - (FAM) - (14-98); high score means a better outcome. |
Change from baseline Functional Assessment Measure - Cognitive subscale at 2 weeks and 4 weeks
|
|
Neuropsychological outcomes
Zeitfenster: Change from baseline Quality of Life Questionnaire for aphasics at 2 weeks and 4 weeks
|
Quality of Life questionnaire for Aphasics (QLQA) - (0-148); High score means a better outcome. |
Change from baseline Quality of Life Questionnaire for aphasics at 2 weeks and 4 weeks
|
|
Neuropsychological outcomes
Zeitfenster: Change from baseline The semi-structured scale for functional evaluation of personal neglect at 2 weeks and 4 weeks
|
The semi-structured scale for functional evaluation of personal neglect - (0-9); High score means a worse outcome. |
Change from baseline The semi-structured scale for functional evaluation of personal neglect at 2 weeks and 4 weeks
|
|
Neuropsychological outcomes
Zeitfenster: Change from baseline Barrage Test at 2 weeks and 4 weeks
|
Barrage test (0-36). High score means a better outcome. |
Change from baseline Barrage Test at 2 weeks and 4 weeks
|
|
Neuropsychological outcomes
Zeitfenster: Change from baseline Letter cancellation test at 2 weeks and 4 weeks
|
Letter cancellation test - (0-104). High score means a better outcome. |
Change from baseline Letter cancellation test at 2 weeks and 4 weeks
|
|
Neuropsychological outcomes
Zeitfenster: Change from baseline Sentence reading test at 2 weeks and 4 weeks
|
Sentence reading test (0-6). High score means a worse outcome. |
Change from baseline Sentence reading test at 2 weeks and 4 weeks
|
|
Neuropsychological outcomes
Zeitfenster: Change from baseline Wundt-Jastrow area illusion test at 2 weeks and 4 weeks
|
Wundt-Jastrow area illusion test (0-20). High score means a worse outcome. |
Change from baseline Wundt-Jastrow area illusion test at 2 weeks and 4 weeks
|
|
Neuropsychological outcomes
Zeitfenster: Change from baseline The semi structured scale for the functional evaluation of extrapersonal neglect at 2 weeks and 4 weeks
|
The semi structured scale for the functional evaluation of extrapersonal neglect (0-9). High score means a worse outcome. |
Change from baseline The semi structured scale for the functional evaluation of extrapersonal neglect at 2 weeks and 4 weeks
|
|
Neurophysiological outcome
Zeitfenster: Change from baseline oscillation at 2 weeks and 4 weeks
|
The ratio of fast (8-30 Hz, α-β) to slow (2-8 Hz, δ-θ) oscillation amplitude at the midline electrodes (Fz, Cz, Pz, Oz) will be measured and compared pre- and post intervention." |
Change from baseline oscillation at 2 weeks and 4 weeks
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Caregiver psychological distress
Zeitfenster: Change from baseline Back depression Inventory II at 2 weeks and 4 weeks
|
Back depression Inventory II (BDI II) - (0-63). High score means a worse outcome. |
Change from baseline Back depression Inventory II at 2 weeks and 4 weeks
|
|
Caregiver psychological distress
Zeitfenster: Change from baseline State-trait anxiety inventory; at 2 weeks and 4 weeks
|
State-trait anxiety inventory (STAI-Y). It is composed by two scales: STAI-Y State (20-80) and STAI-Y Trait (20-80). High score means a worse outcome. |
Change from baseline State-trait anxiety inventory; at 2 weeks and 4 weeks
|
|
Caregiver psychological distress
Zeitfenster: Change from baseline Questionario psicofisiologico (CBA) at 2 weeks and 4 weeks
|
Psychophysiological Questionnaire (30-120). WHOQOL-BREF. |
Change from baseline Questionario psicofisiologico (CBA) at 2 weeks and 4 weeks
|
|
Caregiver psychological distress
Zeitfenster: Change from baseline Prolonged grief disorder -12 at 2 weeks and 4 weeks
|
Prolonged grief disorder -12 (PG-12) - (11-55). High score means a worse outcome. |
Change from baseline Prolonged grief disorder -12 at 2 weeks and 4 weeks
|
|
Caregiver psychological distress
Zeitfenster: Change from baseline Family strain questionnaire at 2 weeks and 4 weeks
|
Family strain questionnaire (FSQ) - (1-44). High score means a worse outcome. |
Change from baseline Family strain questionnaire at 2 weeks and 4 weeks
|
|
Caregiver psychological distress
Zeitfenster: Change from baseline Wolrd health organization - quality of life at 2 weeks and 4 weeks
|
better outcome. |
Change from baseline Wolrd health organization - quality of life at 2 weeks and 4 weeks
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Mitarbeiter
Mitarbeiter
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Neurologische Manifestationen
- Zerebrovaskuläre Erkrankungen
- Erkrankungen des Gehirns
- Erkrankungen des zentralen Nervensystems
- Erkrankungen des Nervensystems
- Gefäßerkrankungen
- Herz-Kreislauf-Erkrankungen
- Psychische Störungen
- Neurobehaviorale Manifestationen
- Neurokognitive Störungen
- Kommunikationsstörungen
- Sprachstörungen
- Sprachstörungen
- Pathologische Zustände, Anzeichen und Symptome
- Anzeichen und Symptome
- Streicheln
- Aphasie
- Bewusstseinsstörungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- 345
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .